A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma
NCT ID: NCT01472198
Last Updated: 2015-03-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
250 participants
INTERVENTIONAL
2011-11-30
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
NCT02399137
Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer
NCT01956812
Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer
NCT00652054
Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer
NCT01851174
Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint
NCT00613730
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simtuzumab (open-label)
Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
Simtuzumab
Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Gemcitabine
Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Simtuzumab 200 mg (randomized)
Participants will receive simtuzumab 200 mg plus gemcitabine in cycles of 28 days for up to 3 years.
Simtuzumab
Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Gemcitabine
Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Simtuzumab 700 mg (randomized)
Participants will receive simtuzumab 700 mg plus gemcitabine in cycles of 28 days for up to 3 years.
Simtuzumab
Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Gemcitabine
Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Placebo (randomized)
Participants will receive placebo to match simtuzumab plus gemcitabine in cycles of 28 days for up to 3 years.
Gemcitabine
Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Placebo to match simtuzumab
Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simtuzumab
Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Gemcitabine
Gemcitabine 1000 mg/m\^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
Placebo to match simtuzumab
Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The presence of measurable metastatic pancreatic cancer documented by contrast enhanced CT (or MRI) scan in addition to 1 of the following:
1. Histological diagnosis of pancreatic adenocarcinoma confirmed by pathologist OR
2. Pathologist confirmed histological/cytological diagnosis of adenocarcinoma consistent with pancreatic origin in conjunction with either:
1. The presence of a mass in the pancreas OR
2. A history of resected pancreatic carcinoma
* Measurable disease per RECIST (ver. 1.1)
* ECOG Performance Status of 0 or 1.
* Adequate hepatic, hematologic and renal functions.
Exclusion Criteria
* A diagnosis of pancreatic islet neoplasms.
* Subject has undergone major surgery other than diagnosis surgery within 4 weeks of randomization
* Presence of biliary obstruction requiring external drainage
* Brain metastases.
* Unstable cardiovascular function within the last 6 months of screening
* Clinically active liver disease, including active viral hepatitis (HBV or HCV) or cirrhosis
* Known HIV infection.
* Uncontrolled hypertension at Screening
* History or presence of any form of cancer, other than pancreatic cancer, within the 3 years prior to enrollment
* Prior or concurrent anti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, retinoid therapy, hormonal therapy) for the treatment of inoperable locally advanced or metastatic pancreatic cancer; prior radiotherapy and chemotherapy given as pre-operative neoadjuvant therapy or radio sensitizers for locally advanced pancreatic cancer are allowed.
* Uncontrolled systemic fungal, bacterial or viral infection
* Participation in an investigational drug or device trial with therapeutic intent within 30 days prior to study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zung Thai, MD
Role: STUDY_DIRECTOR
Gilead Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham Hematology and Oncology Associates, LLC
Birmingham, Alabama, United States
University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States
Central Hematology Oncology Medical Group, Inc.
Alhambra, California, United States
Comprehensive Blood and Cancer Center
Bakersfield, California, United States
California Cancer Associates for Research and Excellence (CCARE)
Fresno, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
UCLA Community Oncology Practice
Los Angeles, California, United States
Stanford University Medical Center
Palo Alto, California, United States
Wilshire Oncology Medical Group, Inc.
Rancho Cucamonga, California, United States
Sharp Health Care
San Diego, California, United States
San Jose Medical Group
San Jose, California, United States
Saint Mary's Regional Cancer Center
Grand Junction, Colorado, United States
Hematology Oncology Associates, PC
Stamford, Connecticut, United States
Florida Cancer Specialists
Tampa, Florida, United States
Georgia Cancer Specialists, P.C.
Atlanta, Georgia, United States
Northwestern University
Chicago, Illinois, United States
Oncology Hematology Care, Inc.
Crestview Hills, Kentucky, United States
Anne Arundel Medical Center, Annapolis Oncology Center
Annapolis, Maryland, United States
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Providence Cancer Center Oncology and Hematology Care Clinic-Eastside Portland
Southfield, Michigan, United States
Hematology and Oncology Associates at BridgePoint
Tupelo, Mississippi, United States
Saint Joseph Oncology, Inc.
Saint Joseph, Missouri, United States
Washington University School of Medicine
St Louis, Missouri, United States
Montana Cancer Institute Foundation c/o Montana Cancer Specialists
Missoula, Montana, United States
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, United States
Saint Luke's-Roosevelt Hospital Center
New York, New York, United States
Beth Israel Comprehensive Cancer Center
New York, New York, United States
Duke University Medical Center, Comprehensive Cancer Center
Durham, North Carolina, United States
Emerywood Hematology and Oncology
High Point, North Carolina, United States
Oncology Hematology Care, Inc.
Blue Ash, Ohio, United States
PinnacleHealth
Harrisburg, Pennsylvania, United States
Abington Hematology Oncology Associates, Inc.
Willow Grove, Pennsylvania, United States
Charleston Hematology Oncology Associates, PA
Charleston, South Carolina, United States
South Carolina Oncology Associates
Columbia, South Carolina, United States
Tennessee Cancer Specialists
Knoxville, Tennessee, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
Coastal Bend Cancer Center
Corpus Christi, Texas, United States
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
San Antonio Military Medical Center
Fort Sam Houston, Texas, United States
Center for Cancer and Blood Disorders, PC
Fort Worth, Texas, United States
Joe Arrington Cancer Research and Treatment Center
Lubbock, Texas, United States
Utah Cancer Specialists
Salt Lake City, Utah, United States
Virginia Cancer Specialists, PC
Fairfax, Virginia, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Republic Clinical Oncology Dispensary of the Ministry of Healthcare of Republic of Bashkortostan
Ufa, Bashkortostan Republic, Russia
Regional Oncology Dispensary
Ivanovo, Ivanovo Oblast, Russia
Medical Radiological Research Center of Russian Academy of Medical Sciences, Obninsk
Obninsk, Kaluga Oblast, Russia
Kursk Regional Oncologic Dispensary
Kursk, Kursk Oblast, Russia
Blokhin Cancer Research Center of Russia, Dept. of clinical pharmacology
Moscow, Moscow, Russia
State Institution "Blokhin Cancer Research Centre RAMS"
Moscow, Moscow, Russia
Non-State Institution of healthcare "Central Clinical Hospital #1 OAO RZD
Moscow, Moscow, Russia
Non-state Healthcare Institution "N.A. Semashko Central Clinical Hospital #2 of JSC "Russian Railway
Moscow, Moscow, Russia
State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
Arkhangelsk, Primorskiy (Maritime) Kray, Russia
Republican Clinical Oncologic Dispensary of Ministry of health of Republic Tatarstan
Kazan', Tatarstan Republic, Russia
State Budgetary Healthcare Institution "Nizhny Novgorod Regional Oncological Dispensary"
Nizhny Novgorod, , Russia
Budgetary Healthcare Institution of Omsk Region "Clinical Oncologic Dispensary"
Omsk, , Russia
Petrov Research Oncology Institute
Saint Petersburg, , Russia
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Benson AB 3rd, Wainberg ZA, Hecht JR, Vyushkov D, Dong H, Bendell J, Kudrik F. A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma. Oncologist. 2017 Mar;22(3):241-e15. doi: 10.1634/theoncologist.2017-0024. Epub 2017 Feb 28.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS-US-324-0101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.